Acquired factor V inhibitor

Summary

Acquired factor V(FV) inhibitors as a rare bleeding disorder, poses a formidable challenge to treating physicians with limited evidence to guide its management. We systematically reviewed our experience in Singapore and the published literature to determine possible answers to clinical questions formulated on the manifestation and best management of non-bovine thrombin and non-congenital acquired FV inhibitors. The incidence in Singapore was 0.09 cases per million person years (3 cases over 10 years). Seventy-three other cases meeting pre-defined search criteria were found in the published literature. Bleeding occurred in 68.4% of these patients, with mucous membranes being the most common site. Intracranial and retroperitoneal bleeds carried the highest mortality. The mortality rate from bleeding was 12%. There was a tendency for FV levels and PT/aPTT prolongation to predict bleeding but not the inhibitor level. No consistently effective haemostatic agent could be determined, but platelet transfusion should probably be the first line therapy. Among bleeding patients, inhibitors tended to disappear faster with inhibitor elimination therapy (IET) compared to without IET (60 vs. 150 days, p=0.299). IET made no significant difference among non-bleeding patients (p=0.511) and is thus recommended for bleeding patients or those with high bleeding risk. Steroids as single agent IET was effective in the majority of patients. Logical management approaches may be drawn but are limited by small sample size, heterogeneity of reports, and potential publication bias. The inception of a comprehensive registry will provide more reliable data that may verify our findings.

Keywords

Haemostasis - acquired coagulation disorders - management of disease - factor V inhibitors

• References

• 1 Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002; 42: 18-26.
• 2 Knobl P, Lechner K. Acquired factor V inhibitors. Baillieres Clin Haematol 1998; 11: 305-318.
• 3 Hoffman R, Benz Jr EJ, Shattil SJ. et al. In: Haematology: Basic Principles and Practice, 4^th Edition. Churchill Livingstone. 2005 Chapter 123.
• 4 Ortel TL. Clinical and laboratory manifestations of anti-factor V antibodies. J Lab Clin Med 1999; 133: 326-334.
• 5 Favaloro EJ, Posen J, Ramakrishna R. et al. Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation. Blood Coagul Fibrinolysis 2004; 15: 637-647.
• 6 Lian EC, Tzakis AG, Andrews D. Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis. Am J Hematol 2004; 77: 363-365.
• 7 Takaku T, Kuriyama Y, Shoji N. et al. Simultaneous development of factor V inhibitor and autoimmune thrombocytopenia in a patient with dermatomyositis (English abstract). Rinsho Ketsueki 2002; 43: 1050-1054.
• 8 Leroy-Matheron C, Mallat A, Duvoux C. et al. Inhibitor against coagulation factor V after liver transplantation. Transplantation 1999; 68: 1054-1056.
• 9 Smith JD, Sindhi R, Rogers R. et al. Factor V inhibitor in a liver transplant patient associated with porcine xenoperfusion. Ann Clin Lab Sci 1998; 28: 280-282.
• 10 Kamphuisen PW, Haan J, Rosekrans PC. et al. Deep-vein thrombosis and coumarin skin necrosis associated with a factor V inhibitor with lupus-like features. Am J Hematol 1998; 57: 176-178.
• 11 Gordon B, Haire W, Duggan M. et al. Factor V inhibitor developing after liver transplantation in a 3-year-old child. Pediatrics 1991; 88: 156-159.
• 12 Massignon D, Roullit S, Espinouse D. et al. Occur-rence of a circulating anticoagulant, factor V inhibitor after surgical intervention. Ann Fr d Anesth Reanim 1989; 08: 70-72.
• 13 Lazarchick J, Wolff CM, Pepkowitz SH. et al. Factor V inhibitor associated with immune complex formation. Arch Pathol Lab Med 1986; 110: 448-451.
• 14 Nesheim ME, Nichols WL, Cole TL. et al. Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest 1986; 77: 405-415.
• 15 Vickars LM, Coupland RW, Naiman SC. The response of an acquired Factor V inhibitor to activated Factor IX concentrate. Transfusion 1985; 25: 51-53.
• 16 Lane TA, Shapiro SS, Burka ER. Factor V antibody and disseminated intravascular coagulation. Ann Intern Med 1978; 89: 182-185.
• 17 Coots MC, Muhleman AF, Glueck HI. Hemorrhagic death associated with a high titer factor V inhibitor. Am J Hematol 1978; 04: 193-206.
• 18 Crowell Jr EB. Observations on a factor-V inhibitor. Br J Haematol 1975; 29: 397-404.
• 19 Stenbjerg S, Husted S, Mygind K. A circulating factor V inhibitor: possible side effect of treatment with streptomycin. Scand J Haematol 1975; 14: 280-285.
• 20 Feinstein DI, Rapaport SI, Chong MM. Factor V inhibitor: report of a case, with comments on a possible effect of streptomycin. Ann Intern Med 1973; 78: 385-388.
• 21 de Raucourt E, Barbier C, Sinda P. et al. High-dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors. Am J Hematol 2003; 74: 187-190.
• 22 Ferguson JH, Johnston Jr CL, Howell DA. A ciruclating inhibitor (anti-AcG) specific for the labile factor-V of the blood-clotting mechanism. Blood 1958; 13: 382-397.
• 23 Handley DA, Duncan BM. A circulating anticoagulant specific for factor V. Pathology 1969; 01: 265-272.
• 24 Feinstein DI, Rapaport SI, McGehee WG. et al. Factor V Anticoagulants: Clinical, Biochemical, and Immunological Observations. J Clin Invest 1970; 49: 1578-1588.
• 25 Leus B, Devreese K, van den Bossche J. et al. Factor V inhibitor: case report. Blood Coagul Fibrinolysis 2006; 17: 585-587.
• 26 Bayani N, Rugina M, Haddad-Vergnes L. et al. High-titer acquired factor V inhibitor responsive to corticosteroids and cyclophosphamide in a patient with two malignant tumors. Am J Hematol 2002; 71: 33-36.
• 27 Van Spronsen DJ, Oosting JD, Hoffmann JJ. et al. Factor V inhibitor associated with cold agglutinin disease. Ann Hematol 1998; 76: 49-50.
• 28 Brickner LA, Scannell KA, Sahud MA. Acquired factor V inhibitor in a patient with acquired human immunodeficiency syndrome. Am J Hematol 1996; 52: 332-333.
• 29 Denis A, Baudeau C, Verdy E. et al. Acquired circulating anticoagulant with anti-factor V activity in AIDS: first case report. Nouv Rev Fr Hematol 1995; 37: 165-169.
• 30 Koyama T, Saito T, Kusano T. et al. Factor V inhibitor associated with Sjogren’s syndrome. Br J of Haematol 1995; 89: 893-896.
• 31 Grigg AP, Dauer R, Thurlow PJ. Bleeding due to an acquired inhibitor of platelet associated factor V. Aus NZ J Med 1989; 19: 310-314.
• 32 Okajima A, Horii J, Nasu K. et al. Factor V inhibitor with double cancer. Rinsho Ketsueki 1989; 30: 514-519.
• 33 Takahashi H, Fuse I, Abe T. et al. Acquired factor V inhibitor complicated by Hashimoto’s thyroditis, primary biliary cirrhosis and membranous nephropathy. Blood Coagul Fibrinolysis 2003; 14: 87-93.
• 34 George S, Nagabhushana MS, Cyran EM. Coagulopathy due to an acquired factor V inhibitor and subsequently thrombosis. Am J Hematol 1995; 49: 98-100.
• 35 Taillan B, Fuzibet JG, Vinti H. et al. Factor V inhibitor in celiac disease. Am J Med 1989; 87: 360.
• 36 Bryning K, Leslie J. Factor V inhibitor and bullous pemphigoid. Br Med J 1977; 02: 677-678.
• 37 Kyriakou DS, Alexandrakis MG, Passam FH. et al. Acquired inhibitors to coagulation factors in patients with gastrointestinal disease. Eur J Gastroenterol Hepatol 2002; 14: 1383-1387.
• 38 Suehisa E, Toku M, Akita N. et al. Study on an antibody against F2F2 fragement of human factor V in a patient with Hashimoto’s dsease and Bullous Pemphigoid. Thromb Res 1995; 77: 63-68.
• 39 Godart B, Boinot C, Remblier C. et al. Acquired factor V inhibitor associated with valproic acid use in a cirrhotic patient. Gut 2006; 55: 134-135.
• 40 Shastri KA, Ho C, Logue G. An acquired factor V inhibitor: clinical and laboratory features. J Med 1999; 30: 357-366.
• 41 Fu YX, Kaufman R, Rudolph AE. et al. Multimodality therapy of an acquired factor V inhibitor. Am J Hematol 1996; 51: 315-318.
• 42 Smid WM, de Wolf JT, Nijland JH. et al. Severe bleeding caused by an inhibitor to coagulation factor V: a case report. Blood Coagul Fibrinolysis 1994; 05: 133-137.
• 43 Brandt JT, Britton A, Kraut E. A spontaneous factor V inhibitor with unexpected laboratory features. Arch Pathol Lab Med 1986; 110: 224-227.
• 44 Chediak J, Ashenhurst JB, Garlick I. et al. Successful management of bleeding in a patient with factor V inhibitor by platelet transfusions. Blood 1980; 56: 835-841.
• 45 Ortal TL, Moore KD, Quinn-Allen MA. et al. Inhibitory anti-factor V antibodies bind to factor C2 domain and are associated with hemorrhagic manifestations. Blood 1998; 91: 4188-4196.
• 46 Lopez V, Pflugshaupt R, Butler R. A specific inhibitor of human clotting factor V. Acta Haematol 1968; 40: 275-285.
• 47 Onoura CA, Lindenbaum J, Hymie LN. Massive hemorrhage associated with circulating antibodies to factor V. Am J Med Sci 1973; 265: 407-417.
• 48 Okoshi Y, Akiyama H, Inoue T. et al. A long-lasting idiopathic factor V inhibitor. Rinsho Ketsueki 2003; 44: 14-18.
• 49 Jansen M, Schmaldienst S, Banyai S. et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 2001; 112: 91-97.
• 50 Kapur A, Kelsey PR, Isaacs PE. Factor V inhibitor in thrombosis. Am J Hematol 1993; 42: 384-388.
• 51 Chong LL, Wong YC. A case of factor V inhibitor. Am J Hematol 1985; 19: 395-399.
• 52 Hasegawa M, Tanaka T, Kii T. et al. Acquired inhibitor against coagulation factor V with severe haematuria. Rinsho Ketsueki 2003; 44: 933-939.
• 53 Azjner E, Balogh I, Haramura G. et al. Anti-factor V autoantibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding. J Thromb Haemost 2003; 01: 943-949.
• 54 Chiu HC, Rao AK, Beckett C. et al. Immune complex containing factor V in a patient with an acquired neutralizing antibody. Blood 1985; 65: 810-818.
• 55 Lu L, Liu Y, Wei J. et al. Acquired inhibitor of factor V: first report in China and iterature review. Haemophilia 2004; 10: 661-664.
• 56 Lerolle D, Dreyer-Dufer C, Allain JP. A circulating inhibitor specific to factor V. Clinical, biological and therapeutic study. Nouv Presse Med 1981; 10: 1483-1487.
• 57 Tribl B, Knobl P, Derfler K. et al. Rapid elimination of a high-titre spontaneous factor V antibody by extra-corporeal antibody-based immunoadsorption and immunosuppression. Ann Haematol 1995; 71: 199-203.
• 58 Perdekamp MT, Rubenstein DA, Jesty J. et al. Platelet factor V supports hemostasis in a patient with an acquired factor V inhibitor, as shown by prothrombinase and tenase assays. Blood Coagul Fibrinolysis 2006; 17: 593-597.
• 59 Gacina P, Kusec R, Carzavec D. et al. Acquired factor V inhibitor: a case report. Acta Clin Croat 2006; 45: 199-201.
• 60 Endo H, Kawauchi K, Tomimatsu M. et al. Acquired factor V inhibitor responsive to corticosteroids in a patient with double cancers. Intern Med 2007; 46: 621-625.
• 61 Jeimy SB, Krakow EF, Fuller N. et al. An acquired factor V inhibitor associated with defective factor V function, storage and binding to multimerin 1. J Thromb Haemost 2008; 06: 395-397.
• 62 Lebrun A, Leroy-Matheron C, Arlet JB. et al. Successful treatment with rituximab in a patient with an acquired factor V inhibitor. Am J Hematol 2008; 83: 163-164.
• 63 Maughan EO, Wilson J, Wilde JT. Spontaneous resolution of acquired factor V inhibitor associated with ovarian carcinoma. Int J Lab Hematol 2007; 29: 316-319.
• 64 Milojkovic D, Patel R, Ford E. et al. Acquired factor V inhibitor after haematopoietic stem cell transplantation. Thromb Haemost 2007; 98: 685-687.
• 65 William BM. Adjunctive role for recombinant activated factor VII in the treatment of bleeding secondary to a factor V inhibitor. Blood Coagul Fibrinolysis 2008; 19: 327-328.
• 66 Lucia JF, Aguilar C. A case of an asymptomatic idiopathic inhibitor to coagulation factor V. Haemophilia 2005; 11: 178-180.
• 67 Gadelha T, Aquino JHW, Silva EA. et al. The Diversity in Clinical Presentation of Acquired Factor V inhibitor. Two case reports. Acta Haematol 2008; 119: 108-110.
• 68 Department of Statistics, Ministry of Trade and Industry, Singapore.. The Yearbook of Statistics Singapore, 2007. Singapore: Department of Statistics; 2007
• 69 Collins PW, Hirsch S, Baglin TP. et al UK Haemophilia Centre Doctors’ Organisation.. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 2007; 109: 1870-1877.
• 70 Favaloro EJ, Bonar R, Duncan E. et al (on behalf of the RCPA QAP in Haematology Haemostasis Committee). Identification of factor inhibitors by diagnostic haemostasis laboratories: A large multi-centre evaluation. Thromb Haemost 2006; 96: 73-78.
• 71 Favaloro EJ, Bonar R, Duncan E. et al (on behalf of the RCPA QAP in Haematology Haemostasis Committee). Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation. Pathology 2007; 39: 504-511.
• 72 Delgado J, Jimenez-Yuste V, Hernandez-Navarro F. et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121: 21-35.
• 73 Turecek PL, Váradi K, Gritsch H. et al. FEIBA: mode of action. Haemophilia. 2004 Suppl 2: 3-9.
• 74 Mittal S, Watson HG. A critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions. Br J Haematol 2006; 133: 355-363.